| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 48 Number 6
Volume 48 Number 5
Volume 48 Number 4
Volume 48 Number 3
Volume 48 Number 2
Volume 48S Number 1
Earlier issues
Volume 48 Number 3 Volume 48 Number 4 Volume 48 Number 5

previous article next article

Research articles

ScienceAsia 48 (2022): 387-392 |doi: 10.2306/scienceasia1513-1874.2022.055


UNC119 promotes the malignant progression of nasopharyngeal carcinoma cells by regulating Wnt/β-catenin pathway


Feilong Honga, Yanjiao Maob, Xinwen Huangc,*

 
ABSTRACT:     UNC119, also known as human retinal gene 4 (HRG4), has been found to contribute to the tumorigenesis of hepatocellular carcinoma. However, the role and mechanism of UNC119 in nasopharyngeal carcinoma has not been systematically investigated yet. Data from western blot and RT-qPCR assays showed that UNC119 was elevated in nasopharyngeal carcinoma cells and tissues. Functional assays demonstrated that transfection with siRNA targeting UNC119 reduced cell viability and suppressed proliferation, invasion, and migration of nasopharyngeal carcinoma cells. Moreover, silence of UNC119 decreased the protein expressions of N-cadherin and vimentin while, on the other hand, increased the protein expressions of E-cadherin and zonula occludes-1 (ZO-1) to suppress epithelial-mesenchymal transition in nasopharyngeal carcinoma. The protein expressions of Axin2 and adenomatous polyposis coli (APC) were up-regulated, while ?-catenin and matrix metalloproteinase-7 (MMP-7) were down-regulated by silence of UNC119 in nasopharyngeal carcinoma cells. In conclusion, knockdown of UNC119 suppressed cell growth and metastasis, and repressed epithelial-mesenchymal transition in nasopharyngeal carcinoma through inactivation of Wnt/?-catenin pathway.

Download PDF

61 Downloads 414 Views


a Department of Otolaryngology, Hangzhou Hospital of Zhejiang Medical and Health Group, Zhejiang 310022 China
b Department of Oncology Radiotherapy, Hangzhou Cancer Hospital Affiliated to Zhejiang University Medical College, Zhejiang 310008 China
c Department of Emergency, Hangzhou Hospital of Zhejiang Medical and Health Group, Zhejiang 310022 China

* Corresponding author, E-mail: huangxinwen10722@163.com

Received 28 Jul 2021, Accepted 10 Jan 2022